Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 4.55 -9.00% -0.45
ARDS closed down 9.0 percent on Friday, November 15, 2019, on 6 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ARDS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -9.00%
Inside Day Range Contraction -9.00%
Oversold Stochastic Weakness -9.00%

Older signals for ARDS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Antibodies Immunotherapy Monoclonal Antibody Bacterial Infections Healthcare Associated Infections Infections Bacterial Diseases Pathogenic Bacteria Pneumonia Pseudomonas Aeruginosa Targeted Immunotherapy
Is ARDS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 12.84
52 Week Low 4.39
Average Volume 8,331
200-Day Moving Average 8.7415
50-Day Moving Average 6.5318
20-Day Moving Average 5.3992
10-Day Moving Average 5.115
Average True Range 0.413
ADX 30.52
+DI 12.4156
-DI 30.0734
Chandelier Exit (Long, 3 ATRs ) 4.961
Chandelier Exit (Short, 3 ATRs ) 5.629
Upper Bollinger Band 6.2159
Lower Bollinger Band 4.5825
Percent B (%b) -0.02
BandWidth 30.25263
MACD Line -0.4577
MACD Signal Line -0.4764
MACD Histogram 0.0187
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.29
Resistance 3 (R3) 5.31 5.10 5.16
Resistance 2 (R2) 5.10 4.91 5.08 5.12
Resistance 1 (R1) 4.82 4.79 4.72 4.80 5.08
Pivot Point 4.61 4.61 4.55 4.59 4.61
Support 1 (S1) 4.33 4.42 4.23 4.31 4.02
Support 2 (S2) 4.12 4.30 4.10 3.98
Support 3 (S3) 3.84 4.12 3.94
Support 4 (S4) 3.82